<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04388761</url>
  </required_header>
  <id_info>
    <org_study_id>20-000264</org_study_id>
    <nct_id>NCT04388761</nct_id>
  </id_info>
  <brief_title>Feasibility and Safety of Allogeneic Adipose Mesenchymal Stem Cells (aMSCs) Delivery Into Kidney Allografts Procured From Deceased Donors With High Kidney Donor Profile Index (KDPI)</brief_title>
  <official_title>Feasibility and Safety of Allogeneic Adipose Mesenchymal Stem Cells (aMSCs) Delivery Into Kidney Allografts Procured From Deceased Donors With High Kidney Donor Profile Index (KDPI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tambi Jarmi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to test an investigational drug called Adipose Mesenchymal
      Stem Cells (aMSCs) for the treatment of ischemia re-perfusion injury (IRI) in patients that
      have had a kidney transplant.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 1, 2021</start_date>
  <completion_date type="Anticipated">February 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serious Adverse Events (SAEs)</measure>
    <time_frame>1 year</time_frame>
    <description>Number of serious adverse events reported. SAEs will include delayed graft function (30 days post-transplant), difficult to control bleeding (intraoperative), sub-scapular kidney hematoma or arteriovenous fistula formation (24 hours postop), and development of stroke, myocardial infarction, or pulmonary embolism (1 year post-transplant).</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Ischemia Reperfusion Injury</condition>
  <arm_group>
    <arm_group_label>Intra parenchymal injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 subjects will receive AMSCs via direct injection into the kidney parenchyma only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intra-arterial infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 subjects will receive AMSCs via intra-arterial infusion only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intra parenchymal injection &amp; Intra-arterial infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 subjects will receive AMSCs via direct injection into the kidney parenchyma and intra-arterial infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Allogeneic adipose derived mesenchymal stem cells</intervention_name>
    <description>Injection of Allogeneic adipose derived mesenchymal stem cells into the Kidney allograft</description>
    <arm_group_label>Intra parenchymal injection</arm_group_label>
    <arm_group_label>Intra parenchymal injection &amp; Intra-arterial infusion</arm_group_label>
    <arm_group_label>Intra-arterial infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female kidney transplant candidates age 18 and above.

          -  Patient is receiving kidney allograft from deceased donor with KDPI&gt;85%.

          -  Ability of subject to give appropriate consent.

          -  Females of childbearing potential with agreement to use birth control for six months
             post-transplant.

          -  Approved by the Mayo Clinic Transplant Selection Committee.

          -  Signed Authorization for Donation of Anatomical Gifts on file.

        Exclusion Criteria:

          -  Positive pregnancy test at the time of the kidney offer is called for the potential
             recipient.

          -  Kidney transplant potential recipients with active malignancy (except none melanoma
             skin malignancies).

          -  Patients with previous history of solid organ transplant (Heart, Lung, Intestine,
             Kidney and/or Pancreas).

          -  Patients with previous history of bone marrow transplant.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tambi Jarmi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 12, 2020</study_first_submitted>
  <study_first_submitted_qc>May 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2020</study_first_posted>
  <last_update_submitted>May 12, 2020</last_update_submitted>
  <last_update_submitted_qc>May 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Tambi Jarmi</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Reperfusion Injury</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

